Compare COTY & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COTY | ALMR |
|---|---|---|
| Founded | 1904 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2012 | 2026 |
| Metric | COTY | ALMR |
|---|---|---|
| Price | $2.84 | $25.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 5 |
| Target Price | $2.64 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 4.8M | 593.7K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,806,600,000.00 | N/A |
| Revenue This Year | N/A | $59.79 |
| Revenue Next Year | N/A | $39.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.82 | $21.58 |
| 52 Week High | $4.43 | $39.61 |
| Indicator | COTY | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 37.08 |
| Support Level | $2.45 | $23.69 |
| Resistance Level | $2.96 | $29.06 |
| Average True Range (ATR) | 0.10 | 2.90 |
| MACD | 0.03 | -0.93 |
| Stochastic Oscillator | 92.42 | 7.09 |
Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.